Skip to main content
NASDAQ:ADRO

Aduro Biotech Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$2.28
$14.60
52-Week Range N/A
Volume171,500 shs
Average Volume162,237 shs
Market Capitalization$236.61 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.


Aduro Biotech logo

About Aduro Biotech

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
CUSIPN/A
Phone(206) 485-7051
Employees152
Year FoundedN/A

Sales & Book Value

Annual Sales$17.26 million
Book Value$4.07 per share

Profitability

Net Income$-82,370,000.00
Net Margins-230.92%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$236.61 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

659th out of 2,038 stocks

Pharmaceutical Preparations Industry

305th out of 769 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aduro Biotech (NASDAQ:ADRO) Frequently Asked Questions

Is Aduro Biotech a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aduro Biotech stock.
View analyst ratings for Aduro Biotech
or view top-rated stocks.

What stocks does MarketBeat like better than Aduro Biotech?

Wall Street analysts have given Aduro Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aduro Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.
View Aduro Biotech's earnings history
.

What price target have analysts set for ADRO?

2 brokers have issued twelve-month target prices for Aduro Biotech's stock. Their forecasts range from $3.75 to $3.75. On average, they anticipate Aduro Biotech's share price to reach $3.75 in the next twelve months.
View analysts' price targets for Aduro Biotech
or view top-rated stocks among Wall Street analysts.

Who are Aduro Biotech's key executives?

Aduro Biotech's management team includes the following people:
  • Eric L. Dobmeier, Chairman, President & Chief Executive Officer
  • Alan Glicklich, Chief Medical Officer
  • Kirk D. Schumacher, Senior Vice President & General Counsel
  • Tom Frohlich, Chief Business Officer
  • Noopur Liffick, VP-Investor Relations & Corporate Communications

Who are some of Aduro Biotech's key competitors?

What other stocks do shareholders of Aduro Biotech own?

When did Aduro Biotech IPO?

(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aduro Biotech's stock symbol?

Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."

How much money does Aduro Biotech make?

Aduro Biotech has a market capitalization of $0.00 and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($5.15) on an earnings per share basis.

How many employees does Aduro Biotech have?

Aduro Biotech employs 152 workers across the globe.

What is Aduro Biotech's official website?

The official website for Aduro Biotech is www.aduro.com.

Where are Aduro Biotech's headquarters?

Aduro Biotech is headquartered at 740 HEINZ AVENUE, BERKELEY CA, 94710.

How can I contact Aduro Biotech?

Aduro Biotech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at (206) 485-7051 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.